بررسي ميزان و طول مدت تاثير سندوستاتين طولاني اثر در درمان بيماران مبتلا به آكرومگالي

Effectiveness and acting period of Sandostatin LAR in the treatment of acromegaly

Background: Pharmacotherapy of acromegaly has been successful in recent years. The therapeutic efficacy of long-acting sandostatin in the treatment of acromegaly has been established in multiple studies. In this report, we investigated the effectiveness of multiple injections of sandostatin and its acting period in Tehran in 2001. Materials and Methods: In this Quasi-experimental study five diagnosed patients with acromegaly after hypophysectorny were treated with sandostatin LAR and followed up for at least 63 days after injection. After octreotide test, a dose of 30 mg sandostatin was prescribed for 3 injections. Frequency of mean daily growth hormons (GH) less than 5µg/L were compared after the first and the third injections. Then acting time of the drug was assessed. The efficacy of 30 and 40 mg doses were compared in 3 cases. Results: There was no relationship between response rate to octreotide and sandostatin. Frequency of GH<51ag/L after the third injection was higher than that of the first one (P<0.01). Therapeutic effect of the drug continued for 42 days after the treatment in responding patients. Conclusion: Octreotide test (with single dose injection) is not a good method for prediction of patientsʹ response to treatment. Measuring GH after multiple injections is a better method for this purpose. Drug injection interval should be determined separately for each patient.